Shanghai Pharmaceuticals
(OTC) SHPMY
Shanghai Pharmaceuticals Financials at a Glance
Market Cap
$1.40B
Revenue (TTM)
$283.20B
Net Income (TTM)
$5.72B
EPS (TTM)
$1.07
P/E Ratio
7.11
Dividend
$0.29
Beta (Volatility)
0.13 (Low)
Dividend
$0.29
Beta (Volatility)
0.13 (Low)
Price
$7.60
Volume
2
Open
$7.60
Price
$7.60
Volume
2
Open
$7.60
Previous Close
$7.60
Daily Range
$7.60 - $7.60
52-Week Range
$6.83 - $8.32
Dividend
$0.29
Beta (Volatility)
0.13 (Low)
Price
$7.60
Volume
2
Open
$7.60
Previous Close
$7.60
Daily Range
$7.60 - $7.60
52-Week Range
$6.83 - $8.32
SHPMY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Shanghai Pharmaceuticals
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
49,608
CEO
Da Wei Liu
Website
www.sphchina.comHeadquarters
Shanghai, 200020, CN
SHPMY Financials
Key Financial Metrics (TTM)
Gross Margin
11%
Operating Margin
3%
Net Income Margin
2%
Return on Equity
8%
Return on Capital
10%
Return on Assets
2%
Earnings Yield
14.06%
Dividend Yield
0.04%
Payout Ratio
22.46%
Stock Overview
Market Cap
$1.40B
Shares Outstanding
183.81M
Volume
2
Short Interest
0.00%
Avg. Volume
63.677
Financials (TTM)
Gross Profit
$30.42B
Operating Income
$9.94B
EBITDA
$14.37B
Operating Cash Flow
$6.15B
Capital Expenditure
$2.33B
Free Cash Flow
$3.83B
Cash & ST Invst.
$43.08B
Total Debt
$49.48B
Shanghai Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$68.51B
+4.4%
Gross Profit
$8.00B
+7.3%
Gross Margin
11.67%
N/A
Market Cap
$1.40B
N/A
Market Cap/Employee
$28.28K
N/A
Employees
49,402
N/A
Net Income
$581.09M
+16.6%
EBITDA
$2.50B
+54.9%
Quarterly Fundamentals
Net Cash
$6.39B
-87.3%
Accounts Receivable
$88.98B
+4.3%
Inventory
$45.36B
+16.5%
Long Term Debt
$5.39B
-44.6%
Short Term Debt
$44.09B
+15.8%
Return on Assets
2.46%
N/A
Return on Invested Capital
10.12%
N/A
Free Cash Flow
$3.09B
+24.7%
Operating Cash Flow
$3.80B
N/A